Mitosis Is a Source of Potential Markers for Screening and Survival and Therapeutic Targets in Cervical Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Espinosa, Ana María ^a,b   Alfaro, Ana ^a,b   Roman Basaure, Edgar ^b   Guardado Estrada, Mariano ^b   Palma, Ícela ^c   Serralde, Cyntia ^b   Medina, Ingrid ^a,b   Juárez, Eligia ^b   Bermúdez, Miriam ^b   Márquez, Edna ^d   Borges Ibáñez, Manuel ^b   Muñoz Cortez, Sergio ^b   Alcántara Vázquez, Avissai ^b   Alonso, Patricia ^b   Curiel Valdez, José ^b   Kofman, Susana ^a,b   Villegas, Nicolas ^e   Berumen, Jaime ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN 20; CYCLIN B2; MESSENGER RNA; NUCLEOLAR SPINDLE ASSOCIATED PROTEIN 1; PROTEIN CDKN3; PROTEIN PRC1; PROTEIN SYCP2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CCNB2 GENE; CDC20 GENE; CDKN3 GENE; CELL CYCLE M PHASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOWN REGULATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MITOSIS; NUCLEOTIDE SEQUENCE; NUSAP1 GENE; OVERALL SURVIVAL; PRC1 GENE; PREDICTIVE VALUE; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYCP2 GENE; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MITOSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84873545520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055975     Document Type: Article

References (76)

1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV, (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-65.
2. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, et al. (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103: 368-83.
3. Ostor AG, (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12(2): 186-92.
4. de Sanjose S, Quint W, Alemany L, Geraets DT, Klaustermeier JE, et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048-56.
5. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2: 868-78.
6. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 89-99.
7. Romanowski B, (2011) Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 7: 161-9.
8. Cuzick J, (2010) Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol 117: S11-4.
9. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, et al. (2007) Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56: 1-24.
10. Natunen K, Lehtinen J, Namujju P, Sellors J, Lehtinen M, (2011) Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol 2011: 675858.
11. Hwang SJ, Shroyer KR, (2012) Biomarkers of cervical dysplasia and carcinoma. J Oncol 2012: 507286.
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2008) GLOBOCAN v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available: http://globocan.iarc.fr.
13. McCrory DC, Matchar DB, Bastian L, Datta S, Hasselblad V, et al. (2009) Evaluation of cervical cytology. Evid Rep Technol Assess (Summ) 1999: 1-6.
14. Wright TC, (2007) Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol 50: 313-23.
15. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, et al. (2009) Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 101: 1612-23.
16. Gupta N, Srinivasan R, Rajwanshi A, (2010) Functional Biomarkers in cervical precancer: an overview. Diagn Cytopathol 38: 618-23.
17. Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, et al. (2012) Screening and cervical cancer cure: population based cohort study. BMJ 344: e900.
18. Torti D, Trusolino L, (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 3: 623-636.
19. Knight Z, Lin H, Shokat KM, (2010) Targeting the cancer kinome through polypharmacology. Nature Cancer Rev 12: 130-137.
20. Saxena R, Dwivedi A, (2012) ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 32: 166-215.
21. Yarden Y, Pines G, (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Cancer Rev 12: 553-563.
22. Pecorelli S, (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105: 103-4.
23. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, et al. (1989) The Use of Polymerase Chain Reaction Amplification for the Detection of Genital Human Papillomaviruses (eds Furth, M. & Greaves, M. F.) 209-214 (Cold Spring Harbor, New York).
24. van den Brule AJ, Meijer CJ, Bakels V, Kenemans P, Walboomers JM, (1990) Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol 28: 2739-43.
25. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, et al. (1991) Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Cancer Sci 82, 524-531.
26. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, et al. (2010) A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res 38, W695-W699.
27. Blazejczyk M, Miron M, Nadon R (2007) FlexArray: A statistical data analysis software for gene expression microarrays. Genome Quebec, Montreal, Canada, URL http://genomequebec.mcgill.ca/FlexArray.
28. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121.
29. D'haene B, Vandesompele J, Hellemans J, (2010) Accurate and objective copy number profiling using real-time quantitative PCR. Methods. 50(4): 262-70.
30. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: 2001-2007.
31. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
32. Huang DW, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
33. Bewick V, Cheek L, Ball J, (2004) Statistics review 13: receiver operating characteristic curves. Crit Care 8: 508-12.
34. Lalkhen AG, McCluskey A, (2008) Statistics VI: Clinical tests: sensitivity and specificity. Contin Educ Anaesth Crit Care Pain 8: 221-3.
35. Dehn D, Torkko KC, Shroyer KR, (2007) Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 111: 1-14.
36. Fan J, Upadhye S, Worster A, (2006) Understanding receiver operating characteristic (ROC) curves. CJEM 8: 19-20.
37. Vazquez-Mena O, Medina-Martinez I, Juárez-Torres E, Valeria Barrón E, Espinosa A et al., (2012). Amplified genes can be over expressed, unchanged or down regulated in cervical cancer cell lines. PLoS ONE 2012; 7(3), e32667.
38. Chen Y, Miller C, Mosher R, Zhao X, Deeds J, et al. (2003) Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 63: 1927-35.
39. Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV, et al. (2007) Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 46: 373-84.
40. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, et al. (2005) Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 24: 7094-104.
41. Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, et al. (2007) Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res 67: 7113-23.
42. Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, et al. (2007) Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res 67: 10163-72.
43. Pyeon D, Newton M, Lambert P, den Boon J, Sengupta S, et al. (2007) Fundamental Differences in Cell Cycle Deregulation in Human Papillomavirus-Positive and Human Papillomavirus-Negative Head/Neck and Cervical Cancers. Cancer Res. 67(10): 10163-72.
44. Biewenga P, Buist M, Moerland P, Ver Loren van Themaat E, van Kampen AH, et al. (2008) Gene expression in early stage cervical cancer. Gynecologic Oncology. 108(3): 520-526.
45. Scotto L, Narayan G, Nandula S, Arias-Pulido H, Subramaniyam S, et al. (2008) Identification of Copy Number Gain and Overexpressed Genes on Chromosome Arm 20q by an Integrative Genomic Approach in Cervical Cancer: Potential Role in Progression. Genes, Chromosomes, Cancer. 47(9): 755-765.
46. Buitrago-Pérez A, Garaulet G, Vázquez-Carballo A, Paramio JM, García-Escudero R, (2009) Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling. Current Genomics. 10(1): 26-34.
47. Baleriola C, Millar D, Melki J, Coulston N, Altman P, et al. (2008) Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections. J Clin Virol 42: 22-6.
48. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, et al. (2011) Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 155: 687-97.
49. Giorgi-Rossi P, Franceschi S, Ronco G, (2012) HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer 130: 1387-94.
50. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, et al. (2009) p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 35: 210-20.
51. Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, et al. (2010) Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 34: 1077-87.
52. Wentzensen N, Hampl M, Herkert M, Reichert A, Trunk MJ, et al. (2006) Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. Cancer 107: 2307-13.
53. Draviam VM, Orrechia S, Lowe M, Pardi R, Pines J, (2001) The localization of human cyclins B1 and B2 determines CDK1 substrate specificity and neither enzyme requires MEK to disassemble the Golgi apparatus. J Cell Biol 152: 945-58.
54. Gong D, Ferrell JE, (2010) The roles of cyclin A2, B1, and B2 in early and late mitotic events. Mol Biol Cell 21: 3149-61.
55. Patel D, McCance DJ, (2010) Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes. J Virol 84: 10956-64.
56. Park SH, Yu GR, Kim WH, Moon WS, Kim JH, et al. (2007) NF-Y-dependent cyclin B2 expression in colorectal adenocarcinoma. Clin Cancer Res 13: 858-67.
57. Mo ML, Chen Z, Li J, Li HL, Sheng Q, et al. (2010) Use of serum circulating CCNB2 in cancer surveillance. Int J Biol Markers 25: 236-42.
58. Nakayama KI, Nakayama K, (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369-81.
59. Teissier S, Ben Khalifa J, Mori M, Pautier P, Desaintes C, et al. (2007) New E6/P63 Pathway, Together with a Strong E7/E2F Mitotic Pathway, Modulates the Transcriptome in Cervical Cancer Cells. Journal of virology 81(17): 9368-9376.
60. Demetrick DJ, Matsumoto S, Hannon GJ, Okamoto K, Xiong Y, et al. (1995) Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet Cell Genet 69: 190-2.
61. Gyuris J, Golemis E, Chertkov H, Brent R, (1993) Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75: 791-803.
62. Galamb O, Spisák S, Sipos F, Tóth K, Solymosi N, et al. (2010) Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer 102: 765-73.
63. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, et al. (2010) MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 3: 16.
64. Julien SG, Dubé N, Hardy S, Tremblay ML, (2011) Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11: 35-49.
65. Taylor KJ, Sims AH, Liang L, Faratian D, Muir M, et al. (2010) Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res 12: R39.
66. Mollinari C, Kleman JP, Jiang W, Schoehn G, Hunter T, et al. (2002) PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J Cell Biol 157: 1175-86.
67. Subramanian R, Wilson-Kubalek EM, Arthur CP, Bick MJ, Campbell EA, et al. (2010) Insights into antiparallel microtubule crosslinking by PRC1, a conserved nonmotor microtubule binding protein. Cell 142: 433-43.
68. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, et al. (2006) KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol 172: 363-72.
69. Lens SM, Voest EE, Medema RH, (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10: 825-41.
70. Li C, Lin M, Liu J, (2004) Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis. Oncogene 23: 9336-47.
71. Wang SM, Ooi LL, Hui KM, (2011) Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 17: 6040-51.
72. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, et al. (2011) Identification of early molecular markers for breast cancer. Mol Cancer 10: 15.
73. Li XC, Bolcun-Filas E, Schmenti JC, (2011) Genetic evidence that synaptonemal complex axial elements govern recombination pathway choice in mice. Genetics 189: 71-82.
74. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA, (2006) Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 43: 415-32.
75. Thierry F, Benotmane M, Demeret C, Mori M, Teissier S, et al. (2004) A Genomic Approach Reveals a Novel Mitotic Pathway in Papillomavirus Carcinogenesis. Cancer Res. 64(3): 895-903.
76. Moody CA, Laimins LA, (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-60.